{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:15:32Z","timestamp":1790511332628,"version":"4.1.0"},"reference-count":19,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2019-0015_s_999_w2aab3b7c73b1b6b1aab1c17b1Aa\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Phosphorylated neurofilament heavy (pNfH), a neuronal cytoskeleton protein, might provide a promising blood biomarker of neuronal damage in neurodegenerative diseases (NDDs). The best analytical approaches to measure pNfH levels and whether serum levels correlate with cerebrospinal fluid (CSF) levels in NDDs remain to be determined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0015_s_998_w2aab3b7c73b1b6b1aab1c17b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We here compared analytical sensitivity and reliability of three novel analytical approaches (homebrew Simoa, commercial Simoa and ELISA) for quantifying pNfH in both CSF and serum in samples of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and control subjects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0015_s_997_w2aab3b7c73b1b6b1aab1c17b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>While all three assays showed highly correlated CSF measurements, Simoa assays also yielded high between-assay correlations for serum measurements (\u03f1\u2009=\u20090.95). Serum levels also correlated strongly with CSF levels for Simoa-based measurements (both \u03f1\u2009=\u20090.62). All three assays allowed distinguishing ALS from controls by increased CSF pNfH levels, and Simoa assays also by increased serum pNfH levels. pNfH levels were also increased in FTD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0015_s_996_w2aab3b7c73b1b6b1aab1c17b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>pNfH concentrations in CSF and, if measured by Simoa assays, in blood might provide a sensitive and reliable biomarker of neuronal damage, with good between-assay correlations. Serum pNfH levels measured by Simoa assays closely reflect CSF levels, rendering serum pNfH an easily accessible blood biomarker of neuronal damage in NDDs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2019-0015","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T09:03:31Z","timestamp":1561712611000},"page":"1556-1564","source":"Crossref","is-referenced-by-count":41,"title":["Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches"],"prefix":"10.1515","volume":"57","author":[{"given":"Carlo","family":"Wilke","sequence":"first","affiliation":[{"name":"Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology , University of T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) , University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fani","family":"Pujol-Calder\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology , The Sahlgrenska Academy at University of Gothenburg , Gothenburg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Barro","sequence":"additional","affiliation":[{"name":"Neurologic Clinic, MS Centre and Policlinic, Departments of Medicine, Biomedicine and Clinical Research , University Hospital Basel, University of Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Stransky","sequence":"additional","affiliation":[{"name":"Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology , University of T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) , University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology , The Sahlgrenska Academy at University of Gothenburg , Gothenburg , Sweden"},{"name":"Clinical Neurochemistry Laboratory , Sahlgrenska University Hospital , M\u00f6lndal , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Michalak","sequence":"additional","affiliation":[{"name":"Neurologic Clinic, MS Centre and Policlinic, Departments of Medicine, Biomedicine and Clinical Research , University Hospital Basel, University of Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Deuschle","sequence":"additional","affiliation":[{"name":"Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology , University of T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) , University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Jeromin","sequence":"additional","affiliation":[{"name":"Quanterix Corporation , Lexington, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology , The Sahlgrenska Academy at University of Gothenburg , Gothenburg , Sweden"},{"name":"Clinical Neurochemistry Laboratory , Sahlgrenska University Hospital , M\u00f6lndal , Sweden"},{"name":"Department of Neurodegenerative Disease, UCL Institute of Neurology , University College London, Queen Square , London , UK"},{"name":"UK Dementia Research Institute at UCL , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sch\u00fcle","sequence":"additional","affiliation":[{"name":"Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology , University of T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) , University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kina","family":"H\u00f6glund","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology , The Sahlgrenska Academy at University of Gothenburg , Gothenburg , Sweden"},{"name":"Clinical Neurochemistry Laboratory , Sahlgrenska University Hospital , M\u00f6lndal , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[{"name":"Neurologic Clinic, MS Centre and Policlinic, Departments of Medicine, Biomedicine and Clinical Research , University Hospital Basel, University of Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[{"name":"Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology , University of T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) , University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"2023033110193594476_j_cclm-2019-0015_ref_001_w2aab3b7c73b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247\u201357.","DOI":"10.1212\/WNL.0000000000001642"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_002_w2aab3b7c73b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Wilke C, Preische O, Deuschle C, Roeben B, Apel A, Barro C, et al. Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry 2016;87:1270\u20132.","DOI":"10.1136\/jnnp-2015-312972"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_003_w2aab3b7c73b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014;75:116\u201326.","DOI":"10.1002\/ana.24052"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_004_w2aab3b7c73b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Rohrer JD, Woollacott IO, Dick KM, Brotherhood E, Gordon E, Fellows A, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 2016;87:1329\u201336.","DOI":"10.1212\/WNL.0000000000003154"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_005_w2aab3b7c73b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577\u201389.","DOI":"10.1038\/s41582-018-0058-z"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_006_w2aab3b7c73b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"De Schaepdryver M, Jeromin A, Gille B, Claeys KG, Herbst V, Brix B, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2018;89:367\u201373.","DOI":"10.1136\/jnnp-2017-316605"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_007_w2aab3b7c73b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 2018;90:e22\u201330.","DOI":"10.1212\/WNL.0000000000004761"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_008_w2aab3b7c73b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Gendron TF, Daughrity LM, Heckman MG, Diehl NN, Wuu J, Miller TM, et al. Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann Neurol 2017;82:139\u201346.","DOI":"10.1002\/ana.24980"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_009_w2aab3b7c73b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"McCombe PA, Pfluger C, Singh P, Lim CY, Airey C, Henderson RD. Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis. J Neurol Sci 2015;353:122\u20139.","DOI":"10.1016\/j.jns.2015.04.032"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_010_w2aab3b7c73b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Boylan KB, Glass JD, Crook JE, Yang C, Thomas CS, Desaro P, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84:467\u201372.","DOI":"10.1136\/jnnp-2012-303768"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_011_w2aab3b7c73b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183\u201398.","DOI":"10.1016\/j.jns.2005.03.015"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_012_w2aab3b7c73b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, et al. The Simoa HD-1 Analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J Lab Autom 2016;21:533\u201347.","DOI":"10.1177\/2211068215589580"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_013_w2aab3b7c73b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Pujol-Calderon F, Portelius E, Zetterberg H, Blennow K, Rosengren LE, Hoglund K. Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neurosci Lett 2018;698:58\u201363.","DOI":"10.1016\/j.neulet.2018.12.042"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_014_w2aab3b7c73b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Valentin MA, Ma S, Zhao A, Legay F, Avrameas A. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J Pharm Biomed Anal 2011;55:869\u201377.","DOI":"10.1016\/j.jpba.2011.03.033"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_015_w2aab3b7c73b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, et al. A practical guide to immunoassay method validation. Front Neurol 2015;6:179.","DOI":"10.3389\/fneur.2015.00179"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_016_w2aab3b7c73b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016;54:1655\u201361.","DOI":"10.1515\/cclm-2015-1195"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_017_w2aab3b7c73b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Lundberg M, Curbo S, Reiser K, Masterman T, Braesch-Andersen S, Arestrom I, et al. Methodological aspects of ELISA analysis of thioredoxin 1 in human plasma and cerebrospinal fluid. PLoS One 2014;9:e103554.","DOI":"10.1371\/journal.pone.0103554"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_018_w2aab3b7c73b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Li D, Shen D, Tai H, Cui L. Neurofilaments in CSF as diagnostic biomarkers in motor neuron disease: a meta-analysis. Front Aging Neurosci 2016;8:290.","DOI":"10.3389\/fnagi.2016.00290"},{"key":"2023033110193594476_j_cclm-2019-0015_ref_019_w2aab3b7c73b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Koel-Simmelink MJ, Vennegoor A, Killestein J, Blankenstein MA, Norgren N, Korth C, et al. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J Immunol Methods 2014;402:43\u20139.","DOI":"10.1016\/j.jim.2013.11.008"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2019.57.issue-10\/cclm-2019-0015\/cclm-2019-0015.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0015\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0015\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:48:23Z","timestamp":1680263303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0015\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,3,23]]},"published-print":{"date-parts":[[2019,9,25]]}},"alternative-id":["10.1515\/cclm-2019-0015"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2019-0015","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,9]]}}}